AcuCort has received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start the study ZEQ001. The purpose of the study is to evaluate Zeqmelit® in acute allergic reactions and is part of the upcoming commercialization of the product in the Nordics.
The study, which is a phase IV, open non-randomized low-intervention study, has as its overall objective to obtain real-world experience with Zeqmelit® from patients previously prescribed corticosteroids in tablet form for self-treatment of acute allergic reactions. The study will provide information on availability, security with the treatment and perceived effect in the patients. The study is expected to start in the fourth quarter of 2023 and last until the second quarter of 2024.
In a comment, AcuCort’s CEO, Jonas Jönmark, says:
“The study will be an important part of the upcoming commercialization of Zeqmelit®. Doctors and patients will be given the opportunity to try and gain practical experience of the treatment and provide us with valuable data.”
For further information please contact:
Jonas Jönmark, vd, AcuCort AB
Telefon: 070 365 5400
About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark, Norway and Finland. All in all, it strengthens the company’s assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.